Stock Fundamentals

Company Information

Company Name
X4 Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US98420X1037
CIK: 0001501697
CUSIP: 98420X103
Currency: USD
Full Time Employees: 45
Phone: 857 529 8300
Fiscal Year End: December
IPO Date: Nov 16, 2017
Description:

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Address:

61 North Beacon Street, Boston, MA, United States, 02134

Directors & Officers

Name Title Year Born
Dr. Adam R. Craig M.B.A., M.D., Ph.D. Executive Chair 1966
Mr. John P. Volpone M.B.A. President & COO 1975
Mr. David H. Kirske CFO, Treasurer & Corporate Secretary 1954
Dr. Richard Peters M.D., Ph.D. Founder 1962
Dr. Renato T. Skerlj Ph.D. Founder NA
Dr. Keith T. Flaherty M.D. Founder & Member of Corporate Advisory Board 1971

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Oct 23, 2025 Adam R Craig N/A Purchase 86.21K $2.90 $250.00K
May 16, 2025 Mark Baldry N/A Purchase 1.03K $2.48 $2.56K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Morgan Stanley - Brokerage Accounts 9.47M Mar 31, 2026 10.41% $0.00 15.34%
Empery Asset Management, LP 8.94M Mar 31, 2026 9.84% $44.50 -0.08%
FMR Inc 8.10M Mar 31, 2026 8.91% $0.00 -4.66%
Bain Capital Life Sciences Investors, LLC 7.97M Mar 31, 2026 8.76% $2.97 0.00%
Kalehua Capital Management LLC 7.45M Mar 31, 2026 8.19% $11.83 100.00%
Perceptive Advisors LLC 6.74M Mar 31, 2026 7.41% $0.54 6.70%
Saturn V Capital Management LLC 6.46M Mar 31, 2026 7.10% $4.83 11.31%
Deep Track Capital, LP 6.34M Mar 31, 2026 6.97% $0.43 26.45%
Vanguard Group Inc 3.42M Dec 31, 2025 3.77% $0.00 734.05%
BRAIDWELL LP 3.27M Mar 31, 2026 3.60% $0.45 -2.85%
Rosalind Advisors, Inc. 3.21M Mar 31, 2026 3.54% $5.33 23.36%
Blackstone Inc 2.68M Mar 31, 2026 2.95% $0.04 0.00%
Trails Edge Capital Partners, LP 2.57M Mar 31, 2026 2.83% $2.43 0.00%
Nantahala Capital Management, LLC 2.45M Mar 31, 2026 2.69% $0.37 0.00%
Bvf Inc 2.23M Mar 31, 2026 2.46% $0.29 0.00%
Samsara BioCapital, LLC 1.83M Mar 31, 2026 2.02% $0.74 -6.50%
StemPoint Capital LP 1.70M Mar 31, 2026 1.87% $0.68 89.38%
BlackRock Inc 1.21M Mar 31, 2026 1.33% $0.00 -1.22%
Millennium Management LLC 1.21M Mar 31, 2026 1.33% $0.00 2,062.48%
Woodline Partners LP 1.00M Mar 31, 2026 1.10% $0.02 0.02%

Shares Statistics

Shares Outstanding: 94.32M
Shares Float: 57.41M
% Insiders: 60.70%
% Institutions: 9,960.30%
Short % Float: 3.11%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Small Cap Growth 3.39M 3.72% ▲ 0.00% Feb 28, 2026
2 Vanguard Total Stock Mkt Idx Inv 2.49M 2.73% ▲ 0.00% Apr 30, 2026
3 Morgan Stanley Inst Inception I 2.33M 2.57% ▼ 4.21% Mar 31, 2026
4 Morgan Stanley Inception 2.33M 2.57% ▼ 4.21% Mar 31, 2026
5 EQ/Morgan Stanley Small Cap Growth K 1.82M 2.00% ▲ 10.63% Mar 31, 2026
6 Fidelity Small Cap Growth K6 1.69M 1.86% ▲ 0.00% Feb 28, 2026
7 Fidelity Select Biotechnology 1.69M 1.85% ▲ 0.00% Mar 31, 2026
8 Fidelity Advisor Biotechnology I 1.34M 1.48% ▲ 0.00% Mar 31, 2026
9 Vanguard Institutional Extnd Mkt Idx Tr 925.99K 1.02% ▲ 0.58% Apr 30, 2026
10 Fidelity Extended Market Index 403.42K 0.44% ▼ 0.43% Mar 31, 2026

Valuation Metrics

Enterprise Value: $231.19M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $381.05M
EBITDA: $-89.69M
Book Value: $1.79
Earnings/Share: $-2.07
Profit Margin: 0.00%
Operating Margin: -748.49%
ROA (TTM): -28.33%
ROE (TTM): -104.21%
Revenue (TTM): $9.01M
Revenue/Share (TTM): $0.13
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -90.60%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 10.16x 0.41x 0.36x -9.79x -0.90x
2024-12-31 3.41x 3.46x 0.85x -4.15x -2.78x
2023-12-31 5.34x 1.09x 0.65x -18.61x -0.59x
2022-12-31 5.76x 0.47x 0.52x -21.93x -0.39x
2021-12-31 6.27x 0.54x 0.45x -20.69x -0.48x
2020-12-31 6.97x 0.47x 0.41x -22.27x -0.57x
2019-12-31 13.68x 0.16x 0.20x -21.80x -0.46x
2018-12-31 6.50x 0.44x 0.40x -40.40x -0.33x
2017-12-31 7.45x 0.21x 0.28x -17.38x -0.34x
2016-12-31 0.47x -0.91x 3.20x -9.68x -0.63x
2015-12-31 1.26x -0.57x 1.46x -31.41x -0.17x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about XFOR.US!